Abstract 62P
Background
Atezo SC is approved in >40 countries in the same indications as atezo intravenous (IV). Primary data from the IMscin001 (NCT03735121) and IMscin002 (NCT05171777) trials have shown similar pt-reported outcomes between atezo IV and SC, and a pt preference for atezo SC vs IV. In this exploratory analysis we report satisfaction and preference for atezo SC by BMI and race (Asian vs non-Asian) from the IMscin001 and IMscin002 studies.
Methods
In part 2 of the phase Ib/3 IMscin001 trial (data cut-off: Apr 26, 2022), pts with previously treated locally advanced/metastatic NSCLC were randomized 2:1 to receive atezo SC or IV. In the phase II IMscin002 trial (data cut-off: Nov 9, 2023), pts with resected NSCLC (Stage II, IIIA or selected IIIB [T3N2]) and PD-L1 ≥1% who had prior chemotherapy, and pts with untreated Stage IV NSCLC and PD-L1 ≥50% were randomized 1:1 to receive atezo SC or IV and switched over to the alternative administration route after Cycle 3. In this exploratory analysis of pt preference and choice for atezo SC vs IV, and pt satisfaction with atezo SC, data were summarized by BMI at randomization or by race (Asian vs non-Asian). The analysis by race was only performed using data from IMscin001 as enough Asian pts were enrolled in this trial.
Results
Outcomes are summarized in the table. In IMscin002, irrespective of BMI, most pts preferred atezo SC over IV and most pts chose atezo SC for the continuation period. In both trials, the majority of pts were satisfied/very satisfied with atezo SC irrespective of BMI. Similar satisfaction rates with atezo SC were observed between Asian and non-Asian pts from IMscin001, with 86.7% and 82.2% of pts being satisfied/very satisfied with atezo SC, respectively. Table: 62P
| % | IMscin002 | |||
| BMI quartiles | ||||
| 1 | 2 | 3 | 4 | |
| Preferred method | ||||
| n | 30 | 30 | 30 | 33 |
| IV | 20.0 | 26.7 | 23.3 | 15.2 |
| SC | 73.3 | 63.3 | 63.3 | 81.8 |
| No preference | 6.7 | 10.0 | 13.3 | 3.0 |
| Treatment choice | ||||
| n | 26 | 25 | 27 | 29 |
| IV | 19.2 | 28.0 | 22.2 | 13.8 |
| SC | 80.8 | 72.0 | 77.8 | 86.2 |
| SC satisfaction | ||||
| n | 31 | 33 | 30 | 33 |
| Satisfied/very satisfied | 80.6 | 84.8 | 90.0 | 87.9 |
| Not satisfied or dissatisfied | 12.9 | 9.1 | 10.0 | 12.1 |
| Dissatisfied/very dissatisfied | 6.5 | 6.1 | 0 | 0 |
| IMscin001 | ||||
| BMI quartiles | ||||
| 1 | 2 | 3 | 4 | |
| SC satisfaction | ||||
| n | 37 | 37 | 43 | 38 |
| Satisfied/very satisfied | 78.4 | 86.5 | 83.7 | 84.2 |
| Not satisfied or dissatisfied | 18.9 | 13.5 | 7.0 | 10.5 |
| Dissatisfied/very dissatisfied | 2.7 | 0 | 9.3 | 5.3 |
| Asian | Non-Asian | |||
| n | 30 | 129 | ||
| Satisfied/very satisfied | 86.7 | 82.2 | ||
| Not satisfied or dissatisfied | 10.0 | 13.2 | ||
| Dissatisfied/very dissatisfied | 3.3 | 4.7 | ||
Conclusions
In this analysis, across both IMscin001 and IMscin002 trials, BMI did not play a role in pt satisfaction or preference for atezo SC. Data from the IMscin001 trial did not show any impact of race (Asian vs non-Asian) on patient satisfaction.
Clinical trial identification
NCT03735121 (IMscin001) NCT05171777 (IMscin002).
Editorial acknowledgement
This study is sponsored by F. Hoffmann-La Roche Ltd. Third-party medical writing assistance, under the direction of authors, was provided by Ella Spraggan, MRes, of Ashfield MedComms, an Inizio company, and funded by F. Hoffmann-La Roche Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
B. Chewaskulyong: Financial Interests, Personal and Institutional, Advisory Role: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal and Institutional, Other, Fiduciary role in other board, society, committee or advocacy group: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal and Institutional, Local PI: F. Hoffmann-La Roche Ltd. Z. Zvirbule: Financial Interests, Personal and Institutional, Other, Travel support for attending meetings: F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme, AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK. K.H. Lee: Financial Interests, Personal, Research Funding: Merck; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, Pfizer, Takeda, Eli Lilly, Yuhan, MSD, AstraZeneca. A.Y. Castro Sanchez: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Royalties: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd. A. Bustillos: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Royalties: F. Hoffmann-La Roche Ltd. L.A. Herraez Baranda: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks or ownership: F. Hoffmann-La Roche Ltd. L.X. Liu: Financial Interests, Personal, Full or part-time Employment: Genentech, Inc. S. Kim: Non-Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Novartis, Takeda, Yuhan; Non-Financial Interests, Personal, Invited Speaker: Amgen, Boehringer Ingelheim, Janssen, Novartis, Takeda; Financial Interests, Personal, Research Funding: Yuhan.